Advanced Cancers Associated With Mesothelin Expression
1 clinical trials · Condition
◉ Watch Advanced Cancers Associated With Mesothelin Expression
| Record | Firm | Date |
|---|---|---|
| Study of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression (NCT03872206) | Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2019-04-16 |
Track Advanced Cancers Associated With Mesothelin Expression automatically
Every clearance here is in the API, with alerts when new ones post.